RE:Brillant strategy...This article from "US National Library Of Medecine" is worth reading.
https://ncbi.nlm.nih.gov/pmc/articles/PMC1490266/ Under "Results"
Half of patients refered for Colonoscopy failed to complete the procedure, overwhelmingly because of nonscheduling.
For $375.USD a positive results(having cancer) from SZLS Colonsentry could certainly convince these patients to go through with the Colonoscopy process. And a negative one(no cancer) would reassure these patients, and would save these patients $2.000USD(Colonoscopy).
Doctors and patients would certainly like that.
wildbird1 wrote: In the Aug 14, 2019 PressRelease SZLS said " The company has initiated(set in motion) a contract with a large Health System to improve
patients compliance with cancer screening."
This Quote say's a lots about SZLS strategy.
Doctors are sometime very convervative about the way they test patients. If for a doctor Exas:Us cologuard poop test work fine, the doctor will not try to convince a patient to switch to a blood test (SZLS).The same goes for a Colonoscopy.
What SZLS is telling doctors is SZLS(for now) is not trying to replace Exas:Us Cologuard or a Colonoscopy, SZLS is simply giving doctors an alternative for the non-compliant patients who are not interested to pay $600.USD to poop in a box, or patients that will undergo an expensive colonoscopy (average price $2,000USD) only if they really have to.
https://mdsave.com/procedures/colonoscopy/d783fdcd It's a Win Win situation, doctors keep their prerogative to use Exas:Us Cologuard or a colonoscopy and at the same time they have an alternative (Colonsentry) that will test the non-compliant patients for treatments if necessary and keep these patients in their office (more patients = more money).
Brillant strategy...